ライフサイエンスコーパス: intestinal failure

1 of progressive liver disease in infants with intestinal failure.

2 ral nutrition (PN) is the main treatment for intestinal failure.

3 harm in the form of CCABSIs in children with intestinal failure.

4 for humanised grafts to treat patients with intestinal failure.

5 increased medical and surgical treatment for intestinal failure.

6 ent of irreversible, permanent, and subtotal intestinal failure.

7 rition (HPN) dependence in SBS patients with intestinal failure.

8 ing procedure for patients with irreversible intestinal failure.

9 potentially life-saving treatment of severe intestinal failure.

10 n is a successful treatment for irreversible intestinal failure.

11 ues in adults and children with PN dependent intestinal failure.

12 lts and children with irreversible liver and intestinal failure.

13 le strategy in the treatment of irreversible intestinal failure.

14 periencing life-threatening complications of intestinal failure.

15 standard of care for patients with end-stage intestinal failure.

16 the intestine began to emerge as therapy for intestinal failure.

17 for short bowel syndrome and other types of intestinal failure.

18 onable option for patients with irreversible intestinal failure.

19 tion (TPN) for the treatment of irreversible intestinal failure.

20 ity and mortality from PNALD in infants with intestinal failure.

21 tion and after a mean period of 5.3 years of intestinal failure.

22 now available for patients with irreversible intestinal failure.

23 intestinal transplantation as treatment for intestinal failure.

24 ptimize nutrient absorption in patients with intestinal failure.

25 ollected data from 85 patients with SBS with intestinal failure, according to the European Society fo

26 nfections as well as at an increased risk of intestinal failure after extensive intestinal resection.

27 ng-term total parenteral nutrition (TPN) for intestinal failure and 15% to 40% of adults on home pare

28 f correctly indicated, is a clinical sign of intestinal failure and a surrogate marker for markedly i

29 ifesaving for selected patients with chronic intestinal failure and can be done with minimal risk to

30 be a life-saving procedure for patients with intestinal failure and complex abdominal pathology.

31 e-saving therapy available for patients with intestinal failure and life-threatening complications of

32 Short bowel syndrome (SBS) can lead to intestinal failure and require total or supplemental par

33 from patient records, the Dutch Registry of Intestinal Failure and Transplantation, the Intestinal T

34 valuated after a mean period of 5.1 years of intestinal failure and were similar to the transplant re

35 Children with intestinal failure are at high risk for developing centr

36 m infections (CRBSIs) (1.7/1000 d of PN) and intestinal failure-associated liver disease (IFALD) (51

37 been linked with serum biochemical signs of intestinal failure-associated liver disease (IFALD), whe

38 herapy is a safe and effective treatment for intestinal failure-associated liver disease (IFALD).

39 or to OGD for detecting GOV in children with intestinal failure-associated liver disease and results

40 Intestinal failure-associated liver disease develops in

41 inal failure, unless complicated by advanced intestinal failure-associated liver disease, when liver-

42 or combined with glutamine in patients with intestinal failure because of short-bowel syndrome remai

43 ompare adverse outcomes (fistulation, death, intestinal failure, bleeding requiring intervention) and

44 e onset of liver disease in children >2 with intestinal failure but is not advantageous in patients <

45 Patients with irreversible intestinal failure can then be referred for early small

46 aregivers and a designated multidisciplinary intestinal failure center, to enhance the prospects for

47 vers, working with specialists at designated intestinal failure centers, should develop a structured

48 ation of this group is to establish national intestinal failure databases that can support multicente

49 Advancement in treatment of children with intestinal failure did not lead to change in generally a

50 Because a formal diagnosis of intestinal failure has not always been the key to initia

51 le adult patients with short bowel syndrome, intestinal failure (IF) and dependence on parenteral sup

52 al surgery, Crohn disease (CD) may result in intestinal failure (IF) and dependency on home parentera

53 Children with intestinal failure (IF) depend on parenteral nutrition (

54 evaluate the long-term effects of pediatric intestinal failure (IF) on liver histology.

55 Children with chronic intestinal failure (IF) treated with long-term parentera

56 are the 2 treatment options for irreversible intestinal failure (IF).

57 d histologic liver injury in pediatric-onset intestinal failure (IF).

58 and science of the multidisciplinary care of intestinal failure in children.

59 antation has become a standard treatment for intestinal failure in patients with life-threatening com

60 reatment options available for patients with intestinal failure including the cost of the therapy and

61 atients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight abs

62 Management strategies for the prevention of intestinal failure-induced liver disease include early e

63 In selected cases, surgery for intestinal failure is an option with resection or bypass

64 Septic acute liver and intestinal failure is associated with a high mortality.

65 Loss of vascular access in patients with intestinal failure is considered an indication for intes

66 focus on the importance of multidisciplinary intestinal failure management.

67 An association of intestinal failure, mutations in the NOD2 gene and tuber

68 peutic option for patients with irreversible intestinal failure or short bowel syndrome.

69 ue to improve, its role in the management of intestinal failure patients becomes clearer.

70 Some intestinal failure patients do well with long-term total

71 goal of improving outcomes in all long-term intestinal failure patients including those requiring in

72 transplantation; (3) National registries for intestinal failure patients should be established and or

73 (1) Primary care givers managing intestinal failure patients should establish a link with

74 transplants should be considered earlier in intestinal failure patients that develop liver injury, t

75 plantation and its role in the management of intestinal failure patients.

76 whole organ-scale technology needed to treat intestinal failure patients.There is a need for humanise

77 he point at which to refer the patient to an intestinal failure program offering autologous bowel rec

78 ure patients should establish a link with an intestinal failure programs early and collaboration with

79 ailure programs early and collaboration with intestinal failure programs should be initiated for pati

80 e than 50% 3 months after initiating PN; (2) intestinal failure programs should include both intestin

81 Twenty-four children with intestinal failure received the ethanol lock prophylaxis

82 compared quality of life among patients with intestinal failure receiving home parenteral nutrition (

83 The most common etiology of intestinal failure remains short-gut syndrome, which enc

84 Many patients with intestinal failure require intestinal transplantation (I

85 d children who were 18 years or younger with intestinal failure requiring a central venous catheter.

86 ene are a significant risk factor to acquire intestinal failure requiring home parenteral nutrition.

87 bleeding (RR = 0.74, 95% CI: 0.45-1.23), and intestinal failure (RR = 1.00, 95% CI: 0.64-1.57) were n

88 m in patients with short-bowel syndrome with intestinal failure (SBS-IF) to gain insight into its mec

89 n in patients with short bowel syndrome with intestinal failure (SBS-IF).

90 We report of two patients with intestinal failure secondary to mesenteric ischemia.

91 is an established treatment of irreversible intestinal failure, unless complicated by advanced intes

92 al and surgical management of the child with intestinal failure was presented with a focus on the imp

93 ansplantation is now an accepted therapy for intestinal failure when parenteral nutrition therapy can

94 thrombosis, even in the absence of liver and intestinal failure, when other treatment options for var

95 ed complications (P = 0.02).In patients with intestinal failure who are life dependent on HPS, the ta

96 Infants with intestinal failure who are parenteral nutrition (PN)-dep

97 In patients with intestinal failure who are receiving home parenteral sup

98 catheter related infection in patients with intestinal failure who carry mutations in their NOD2 gen